EMEA-001220-PIP08-20

Table of contents

Key facts

Invented name
Olumiant
Active substance
baricitinib
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0339/2021
PIP number
EMEA-001220-PIP08-20
Pharmaceutical form(s)
  • Tablet
  • Oral suspension
Condition(s) / indication(s)
Treatment of alopecia areata
Route(s) of administration
Oral use
Contact for public enquiries
Eli Lilly & Company Limited

E-mail: eu_paediatric@lilly.com 
Tel. +44 (0)1276 483000

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating